|

Nivolumab + Relatlimab FDC Clinical Trials

2 actively recruiting trials across 2 locations

▲ +1 trial since July 2026

Also known as: Opdualag

Pipeline

Phase 2: 2

Top Sponsors

  • Stanford University1
  • Bristol-Myers Squibb1

Indications

Palo Alto, California1 trial

Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases

Stanford University

Phase 2

San Francisco, California1 trial

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

Local Institution - 0096

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.